# Rare Localized Adverse Reaction to Botulinum Toxin Type A in a Patient Without Allergic History: A Case Report

**Authors:** Roselaine Roratto Muner, Amanda Ambrosio Moreira, Isabela Espasandin, Andrea Damas Tedesco, Alan Cristian Marinho Ferreira, Antony de Paula Barbosa

PMC · DOI: 10.1093/asjof/ojag012 · Aesthetic Surgery Journal. Open Forum · 2026-01-20

## TL;DR

A 50-year-old woman had a rare skin reaction after botulinum toxin injections, which improved with ozone therapy.

## Contribution

This case report highlights a rare localized adverse reaction to botulinum toxin type A and the effectiveness of ozone therapy.

## Key findings

- A patient without allergic history developed a severe localized reaction to botulinum toxin type A.
- Ozone therapy led to significant recovery when standard treatments failed.
- The reaction was not specific to a single brand of botulinum toxin formulation.

## Abstract

Botulinum toxin type A is widely used in aesthetic and therapeutic medicine and is considered safe. Nonetheless, rare adverse reactions can occur, even in patients with no previous allergic history. The authors report the case of a 50-year-old woman who developed a localized inflammatory reaction characterized by erythema, edema, vesicles, burning, and pruritus following injections in the upper face. A reactivity test with another formulation in the subcutaneous tissue of the arm produced an even more severe response, suggesting greater immune reactivity in subcutaneous tissue compared with muscle. Considering the known differences among commercial formulations, including accessory proteins and stabilizers, the test excluded the hypothesis of an allergy specific to a single brand. Standard therapies with corticosteroids and antibiotics failed to produce improvement, whereas ozone therapy led to significant recovery. This case emphasizes the importance of individualized follow-up and highlights the need for further studies to elucidate the immunopathological mechanisms underlying such rare hypersensitivity reactions.

Level of Evidence: 5 (Therapeutic)

## Linked entities

- **Chemicals:** antibiotics (PubChem CID 46874763), ozone (PubChem CID 24823)

## Full-text entities

- **Genes:** HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** pruritus (MESH:D011537), erythema (MESH:D004890), insect (MESH:C000719201), vesicular lesions (MESH:D012872), Allergic (MESH:D004342), papules (MESH:D000169), contact dermatitis (MESH:D003877), autoimmune (MESH:D001327), edema (MESH:D004487), PRESENTATION (MESH:D001946), drug hypersensitivity syndromes (MESH:D063926), skin lesion (MESH:D012871), hypopigmentation (MESH:D017496), muscle (MESH:D019042), pain (MESH:D010146), blisters (MESH:D001768), inflammation (MESH:D007249)
- **Chemicals:** amoxicillin (MESH:D000658), acetylcholine (MESH:D000109), prednisone (MESH:D011241), E (MESH:D004540), lactose (MESH:D007785), NaCl (MESH:D012965), ozone (MESH:D010126), Nabota (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12951081/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12951081/full.md

## References

17 references — full list in the complete paper: https://tomesphere.com/paper/PMC12951081/full.md

---
Source: https://tomesphere.com/paper/PMC12951081